论文部分内容阅读
ISTA制药公司(ISTA Pharmaceuticals Inc．)于1月30日宣布,美国FDA已批准其将药物Xibrom用于治疗白内障术后疼痛的申请。在新闻发布会上,ISTA公司说Xibrom已于2005年3月被FDA批准用于治疗白内障术后眼部炎症。
ISTA Pharmaceuticals Inc. announced on January 30 that the U.S. FDA has approved its use of the drug Xibrom for post-cataract pain. At a news conference, ISTA said Xibrom was approved by the FDA in March 2005 for the treatment of ocular inflammation after cataract surgery.